Table 4.
Combination therapies in WM
| Study | Regimen | No. of patients | Phase of study | ORR % |
|---|---|---|---|---|
| Tam [98] | Fludara/CTX | 9 | II | 88 |
| Tamburini [65] | Fludara/CTX | 49 | II | 78 |
| Weber [64] | Cladribine/CTX | 37 | II | 84 |
| Leblond [99] | Fludarabine vs CAP | 92 | III | 30 vs 11% |
| Owen [1] | Fludara/rituximab | 43 | II | 82 |
| Tam [100] | Fludara/CTX/rituximab | 5 | II | 80 |
| Weber [101] | Cladribine/CTX/rituximab | 27 | II | 94 |
| Hensel [102] | Pentostatin/CTX/rituximab | 17 | II | 90 |
| Dimopoulos [66] | Dex/CTX/rituximab | 72 | II | 83 |
| Treon [68] | CHOP/rituximab | 13 | II | 77 |
| Dimopoulos [103] | CHOP/rituximab vs CHOP | 72 | II | 94 |